UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of ...

How will FDA changes reshape drug approval in 2025 and beyond? Vaccines and complex biologics may face greater headwinds as processes change at a short-staffed agency ...

Under new guidance this week from the FDA’s top brass, annual COVID-19 boosters will be authorized only for people 65 years old and older, as well as people with certain health risks, including ...

EMA Backs First On-Demand, Oral Hereditary Angioedema Drug A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to injectable therapies.